Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

About this update from Kodiak Sciences Inc

[{"type":"text","content":"PALO ALTO, Calif., Aug. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024.\n\n\"Our three clinical programs of tarcocimab, KSI-501 and KSI-101 are making strong operational progress,\" said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. \"The Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy continues to enroll. The Phase 3 DAYBREAK study of tarcocimab and KSI-501 is now actively enrolling patients. DAYBREAK features an innovative study design that includes parallel investigational arms of tarcocimab and KSI-501 against aflibercept in wet AMD, and if successful, could support the marketing authorization applications for both investigational medicines. We have also activated the Phase 1b APEX study of KSI-101 in patients with macular edema secondary to inflammation, and the APEX study is now enrolling patients.\"\n\"This past quarter we also strengthened our executive team with the appointment of leaders from both outside and inside our organization,\" continued Dr. Perlroth. \"From outside the organization, we welcomed Dolly Chang, M.D, M.P.H, Ph.D., to the position of Chief Scientific Officer. Dr. Chang joins Kodiak from Genentech, a member of the Roche Group, where she was responsible for Genentech's early-stage ophthalmology pipeline. Dr. Chang brings deep ophthalmology experience in support of Kodiak's early-stage research programs and late-phase Phase 3 programs. From inside the organization, we made new leadership appointments with the promotions of Almas Qudrat, M.Sc., to Chief Quality Officer and Pablo Velazquez-Martin, M.D., to Chief Medical Officer. These two appointments support Kodiak's commercial-facing manufacturing activities including our URSUS facility and our BLA-facing clinical activities including our new set of pivotal studies. We also recognize the on-going maturation of our triplets biopolymer platform with the promotion of Wayne To, M.Phil., to the position of Chief Technology Officer.\"\n\"We look forward to sharing ongoing progress of our science and development programs and are planning to host an Investor Day on September 23, 2024, with details to be announced ahead of the event,\" concluded Dr Perlroth.\nRecent Business Highlights\nNew leadership appointments:Kodiak welc...

More updates from Kodiak Sciences Inc